Purity
>95%, by SDS-PAGE under reducing conditions and visualized by silver stain
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its ability to inhibit proliferation of the A549 human lung carcinoma cells. The ED 50 for this effect is 100-400 ng/mL.
Source
Mouse myeloma cell line, NS0-derived
Human Semaphorin 5A
(Glu23-Thr765)
Accession # AAC09473IEGRMD Human IgG1
(Pro100-Lys330)N-terminus C-terminus Accession #
N-terminal Sequence
AnalysisGlu23
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
110 kDa (monomer)
SDS-PAGE
133 kDa, reducing conditions
5896-S5 |
| |
Formulation Lyophilized from a 0.2 μm filtered solution in PBS, EDTA and Tween® 20. | ||
Reconstitution Reconstitute at 100 μg/mL in PBS. | ||
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. | ||
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: Semaphorin 5A
Semaphorin 5A (Sema5A, previously called SemaF) is a 140 kDa protein of the semaphorin family of axon guidance molecules (1-4). Class 5 semaphorins are type I transmembrane glycoproteins with an N-terminal Sema domain and multiple juxtamembrane type 1 thrombospondin (TSP) repeats within their extracellular domains (1‑3). Sema5A is expressed developmentally in oligodendrocytes, neuroepithelial cells surrounding retinal axons, the base of limb buds, the cardiac atrial septum and endocardial cushions, and the mesoderm surrounding cranial vessels (4-6). The human Sema5A cDNA encodes a 22 amino acid (aa) signal sequence, a 946 aa extracellular domain (ECD), a 22 aa transmembrane sequence and an 85 aa cytoplasmic portion. Within aa 23 - 765, which includes the sema domain and four of the seven TSP repeats, human Sema5A shares 93% aa identity with corresponding mouse, rat, and canine sequences. Semaphorins typically transduce signals through transmembrane plexins (1, 2). The sema domain of Sema5A binds plexin B3, triggering signaling via HGF R/c-Met (7). Both Sema5A and plexin B3 are expressed postnatally during differentiation and migration of central nervous system oligodendrocytes. However, plexin B3 is not significantly expressed prenatally and therefore unlikely to be the Sema5A receptor during development (7, 8). The Sema5A TSP repeats interact with either heparin sulfate or chondroitin sulfate proteoglycans (HSPG, CSPG) (9). HSPG interaction promotes attraction, while CSPG interaction promotes repulsion and is essential for axon fasciculation, independent of plexin B3 (9, 10). Sema5A mutations have been implicated in the genetic syndrome, cri-du-chat, while some polymorphisms may increase risk for neurodegenerative diseases such as Parkinson’s (3, 11). Sema5A expression may be upregulated in metastatic cancer cells and downregulated in autism (12, 13).
References:
Flannery, E. and M. Duman-Scheel (2009) Curr. Drug Targets 10:611.
Zhou, Y. et al. (2008) Trends Biol. Sci. 33:161.
Simmons, A.D. et al. (1998) Biochem. Biophys. Res. Commun. 242:685.
Oster, S.F. et al. (2003) Development 130:775.
Goldberg, J.L. et al. (2004) J. Neurosci. 24:4989.
Fiore, R. et al. (2005) Mol. Cell. Biol. 25:2310.
Artigiani, S. et al. (2004) EMBO Rep. 5:710.
Worzfeld, T. et al. (2004) Eur. J. Neurosci. 19:2622.
Kantor, D.B. et al. (2004) Neuron 44:961.
Hilario, J.D. et al. (2008) Dev. Biol. 326:190.
Lin, L. et al. (2009) Trends Neurosci. 32:142.
Pan, G-Q. et al. (2009) World J. Gastroenterol. 15:2800.
Melin, M. et al. (2006) Neuropsychobiology 54:64.
Entrez Gene IDs:
9037 (Human); 20356 (Mouse); 310207 (Rat)
Alternate Names:
FLJ12815; sema domain, seven thrombospondin repeats (type 1 and type 1-like); Sema F; SEMA5A; SEMAF; Semaphorin 5A; semaphorin F; semaphorin-5A; Semaphorin-F; semF; transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5A
